PARP6 suppression, either by the PARP inhibitor AZ0108 or small interfering RNA (siRNA)-mediated knockdown, promotes an anti-tumor response in a panel of breast cancer lines as well as in breast cancer xenografts, likely through the MARylation of CHK1 during mitosis (Wang et al., 2018). Here, PARP1 is linked to breast cancer.